Deep Brain Stimulation Devices Market Size, Share & Trends Analysis Report By Product (Single Channel, Dual-Channel), By Application (Parkinson’s Disease, Essential Tremor), By End Use, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global deep brain stimulation devices market size was valued at USD 1.05 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 9.8% from 2022 to 2030. The increasing number of patients suffering from involuntary movements associated with Parkinson’s disease, dystonia, and multiple sclerosis is expected to drive market growth. In addition, increasing demand for minimally invasive techniques due to enhanced patient outcomes is also a high-impact rendering driver for the market. Moreover, the introduction of telehealth consults and eHealth apps to routinely monitor PD patients during the COVID-19 pandemic is further expected to support the deep brain stimulation (DBS) devices market growth over the forecast period.

The outbreak of COVID-19has negatively impacted the market by directly affecting the demand & production, creating a disruption in the supply chain, and increasing the financial burden on firms. To reduce the spread of the coronavirus, brain surgeries have frequently been postponed or even canceled during this timeframe. In worst-affected nations, such as the U.S., Russia, India, Brazil, France, the U.K., Italy, and Spain, neurosurgical operations fell by 55%.

Manufacturers have found it difficult to serve their surgeon customers since some hospitals have restricted access to their facilities or changed access regulations. As a result, they saw a decrease in procedural volumes in 2020, which is expected to stifle market growth. However, globally increased activities in tele-consultancy for follow-up and routine check-ups to address the symptoms of PD patients during the pandemic are playing a key role in improving market growth. Thus, such trends are expected to have a significant impact on the adoption of DBS in upcoming years.

Additionally, most nations across the world have eased lockdown restrictions and recommence certain elective surgeries, thus the market is projected to recover and grow during the forecast period. Companies have been using strategies such as rerouting logistics, sourcing from additional partners, and air freight delivery to deal with supply chain disruptions. In addition, major firms are planning to geographically expand their businesses and establish more warehouses in various areas to conduct their operations through multiple available channels in worst-affected regions to satisfy demand. These characteristics are projected to generate lucrative market growth prospects for the market.

The increasing prevalence of neurological disorders, such as Parkinson’s disease, essential tremor, dystonia, and epilepsy, is a high-impact rendering driver for the market. According to World Health Organization (WHO), neurological diseases contribute 6.3% to the global disease burden and are one of the major causes of mortality worldwide, resulting in 13.2% of deaths in developed countries and 16.8% in low- and middle-income countries. High mortality and disease burden create clinical urgency for the incorporation of long-term solutions such as deep brain stimulators. Furthermore, growing awareness about the massive neurological disease burden has raised the demand for deep brain stimulators as an alternative therapy. This is expected to drive market growth during the forecast period.

Furthermore, technological advancements in DBS technologies are anticipated to create growth opportunities in this market. These technological improvements include robot-assisted implantation, improved microelectrode designs, multi-target stimulation, rechargeable implantable pulse generators, and personalized directed programming. Owing to these advancements, DBS devices are showing fewer adverse effects and improved efficacy & symptomatic relief in patients suffering from Parkinson’s, as compared to the traditional methods. For instance, Abbott's Infinity Deep Brain Stimulation System is a technologically enhanced new DBS that can help patients with their symptoms. It is the first wireless iOS software DBS mobile platform that offers efficient and personalized therapy management with reduced risk of adverse effects.

Countries such as U.S. and Canada have witnessed a high prevalence rate of movement and psychiatric disorders coupled with the increasing geriatric population. For instance, according to Parkinson's Foundation, symptoms of PD are common at an average age of 60. The geriatric population is highly susceptible to these disorders. Similarly, according to Canadian Psychological Association, around 2% of the population are suffering from an obsessive-compulsive disorder. Moreover, an increase in FDA approvals for deep brain stimulation devices in clinical applications, such as tremors, severe obsessive-compulsive disorders, and dystonia, is fueling the market growth. For instance, in March 2020, NeuroPace, Inc. received approval from the U.S. FDA for MRI labeling for its RNS System. These factors are expected to boost the demand for DBS devices in these countries.

Furthermore, severe adverse effects and drug interactions owing to drug absorption by non-targeted sites are anticipated to boost the need for a targeted therapy approach, propelling the demand for DBS devices. These drugs can offer significant improvements in motor function; however, they may lead to adverse effects, particularly when the disease progresses. For instance, constant administration of the drug levodopa may result in long-term complications such as hallucinations, dyskinesia, neurotoxic effects, and severe metabolic changes. Thus, adverse effects such as these drive the clinical need to incorporate alternatives based on targeted therapy approaches, including deep brain stimulators. Thus, boosting the market growth during the forecast period.

Product Insights

Based on the product, the market is segmented into single-channel and dual-channel deep brain stimulation devices. The dual-channel segment is dominating the market with a share of 57.12% in 2021 owing to its higher adoption in surgical procedures. Dual channels is one of the safest and most effective devices used in surgical procedures. Thus, the high prevalence of disabling neurological diseases, the increasing number of surgical procedures for PD, and the growing number of hospitals using dual-channel DBS devices are driving the segment growth. Moreover, technological advancements and new product launches are further impelling segment growth. For instance, in January 2020, Abbott’s Infinity DBS system secured FDA approval for the expanded indication of received approval for Parkinson's disease from the U.S. FDA. This system will allow targeting of the specific area of the brain called internal Globus Pallidus (GPi), which is associated with Parkinson's disease symptoms.

However, the single-channel deep brain stimulation device segment is expected to grow at the highest compound annual growth rate (CAGR) of 10.0% from 2022 to 2030. Healthcare professionals believe that single-channel offers more programming options to neurologists, which led to an increased preference for single-channel DBS devices. According to the Parkinson’s Foundation, the geriatric population is more prone to neurological diseases. For instance, as per the World Ageing 2019 report, it is estimated that globally there were about 703 million people aged 65 years in 2019. Thus, the increasing geriatric population, growing awareness about neurological diseases among patients, and preference by healthcare professionals are anticipated to trigger the segment growth.

Application Insights

Based on application, the market is segmented into pain management, epilepsy, essential tremor, obsessive-compulsive disorders (OCD), depression, dystonia, Parkinson's disease, and others. Parkinson's disease segment is dominating the market with a share of 65.13% in 2021 owing to the increasing number of U.S. FDA approvals for deep brain stimulation therapies and the high prevalence of PD worldwide. In December 2017, Boston Scientific Corporation received approval for the Vercise deep brain stimulation device system from the U.S. FDA for the treatment of PD. According to the Parkinson’s Foundation, around 60,000 people in the U.S. are diagnosed with PD every year. This is expected to drive the segment growth in the coming years.

However, the epilepsy segment is expected to grow at the highest compound annual growth rate (CAGR) of 16.1% from 2022 to 2030. Growing awareness about advanced treatment options for epilepsy coupled with developing healthcare infrastructure is expected to further fuel segment growth in the coming years. According to the World Health Organization (WHO), approximately 50 million people are suffering from epilepsy and it is one of the most common neurological diseases worldwide.DBS is used in epilepsy due to the low therapeutic response of medication in seizures and reduced success rates associated with surgeries. This will further lead to segment growth.

End-Use Insights

In the end-use segment, hospitals dominated the overall market growth with a share of 51.88% in 2021. The growth of this segment can mainly be attributed to the increase in the number of DBS surgeries performed in hospitals and the surge in the prevalence of Parkinson’s disease, essential tremor. Furthermore, the availability of technologically advanced DBS devices coupled with favorable reimbursement policies is expected to drive the hospital market further during the forecast period. For instance, Medtronic offers comprehensive services to secure and maintain coverage as well as payment for various DBS devices.

Furthermore, hospitals are currently advancing in terms of technology, and advanced devices are being extensively used in hospitals to provide better treatment. These devices are not just simplifying treatment procedures, but are also helping provide better, faster, and more accurate results. Mostly, all neurological disorders, including Parkinson’s disease, are diagnosed and treated by professional neurologists, who are available in specialty hospitals, using advanced equipment.

However, the Ambulatory Surgical Centers (ASC) segment is expected to grow at the highest compound annual growth rate (CAGR) of 10.3% from 2022 to 2030. This is due to the lower cost of procedures as compared to hospitals, convenient access to patient care, reduced waiting time, and low infection rate as compared to neurology clinics and hospitals. Furthermore, according to a study conducted by Advancing Surgical Care, 92% of patients were satisfied with the medical care and service provided in the ASCs, thus, boosting the segment growth. In addition, most of the neurosurgeries can now be performed at ASCs, as surgical procedures undertaken here are advanced and less invasive. Thus, the growth of the segment can majorly be attributed to shorter procedure time and ongoing advancements in minimally invasive surgical techniques.

Regional Insights

North America dominated the market with a share of 51.59% in 2021 owing to the increase in government funding and initiatives for raising awareness about Parkinson’s disease (PD) is expected to drive the demand for deep brain stimulators. For instance, in 2015, Parkinson’s Foundation funded more than 40 research projects for PD. In addition, an increase in FDA approvals for deep brain stimulators for the treatment of PD is contributing to the market growth. For instance, in October 2016, St. Jude Medical received approval from the U.S. FDA for its St. Jude Medical Infinity DBS and its directional lead technology for use in the treatment of PD.

Furthermore, the presence of major competitors, availability of sophisticated healthcare infrastructure, and supportive government initiatives are also responsible for the market growth in this region. For instance, the National Institute of Neurological Disorder and Stroke (NINDS) supports research activities related to DBS for determining its safety and effectiveness in the treatment of PD.

However, Asia Pacific is expected to significantly lead the market in the future from 2022 to 2030. This is attributed to the rising prevalence of neurodegenerative disorders coupled with the unmet demand for effective and long-term solutions. Rising awareness about neurological disease treatment options and improvements in the clinical development framework of emerging economies is expected to drive the market growth in this region. Moreover, the presence of high growth opportunities in developing countries such as Japan, China, and India are likely to contribute to the market growth. Furthermore, the establishment of organizations such as the Asia-Pacific Centre for Neuromodulation (APCN), which is founded for conducting research and promoting awareness about the associated benefits of deep brain stimulation, is anticipated to boost regional growth.

Key Companies & Market Share Insights

Key players operating in this industry are increasingly focusing on product launches, technological advancements, and other growth strategies, such as mergers & acquisitions to strengthen their foothold in the market. For instance, in September 2019, LivaNova together with MicroPort Scientific received approval for RegaTM pacemakers from the FDA China. These are the smallest pacemakers in the Chinese cardiac rhythm management market. This approval will strengthen the company’s local presence and expand its footprint in the Chinese market.

Emerging players such as NeuroPace, Inc., and Aleva Neurotherapeutics SA, are considered innovators in the market. Products offered by these competitors have a good price-performance proposition, competitive functionality, and are technologically advanced. These players are focusing on product commercialization activities as well as fundraising activities to support the R&D growth. For instance, in October 2017, NeuroPace, Inc. closed a USD 74 million funding round initiated by OrbiMed Advisors and KCK Groups. The funding will support the company’s ongoing efforts for rapid expansion and commercialization of its FDA-approved DBS product- the NeuroPace RNS system. Some of the key players operating in the global deep brain stimulation devices market include:

• Abbott (St. Jude Medical)

• Medtronic

• Boston Scientific Corporation

• Aleva Neurotherapeutics S.A.

• Nexstim

• LivaNova PLC

• Neuropace Inc.

Deep Brain Stimulation Devices Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global deep brain stimulation devices market report based on product, application, end-use, and region:

• Product Outlook (Revenue USD Million, 2018 - 2030)

  • Single Channel

  • Dual Channel

• Application Outlook (Revenue USD Million, 2018 - 2030)

  • Pain Management

  • Epilepsy

  • Essential Tremor

  • Obsessive-Compulsive Disorder (OCD)

  • Depression

  • Dystonia

  • Parkinson’s Disease

  • Others

• End Use Outlook (Revenue USD Million, 2018 - 2030)

  • Hospitals

  • Neurology Clinics

  • Ambulatory Surgical Centers

  • Research Centers

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE